You have 0 items in your cart
CagriSema and retatrutide are two of the most closely followed programmes in current metabolic research.
They’re frequently discussed together because both represent attempts to move beyond conventional single-pathway GLP-1 research.
Scientifically, however, CagriSema and retatrutide take very different approaches.
One combines two compounds targeting different signalling systems. The other is a single molecule designed to activate three receptors.
Understanding that distinction is essential when comparing the research.
What Is CagriSema?
CagriSema is an investigational combination being developed by Novo Nordisk.
It combines:
Cagrilintide + semaglutide
Cagrilintide is a long-acting analogue of the naturally occurring peptide hormone amylin.
Semaglutide is a GLP-1 receptor agonist.
CagriSema therefore allows researchers to investigate what happens when amylin-related signalling and GLP-1 receptor signalling are targeted simultaneously.
The programme has progressed through Phase 3 clinical research.
What Is Retatrutide?
Retatrutide is an investigational compound being developed by Eli Lilly.
Unlike CagriSema, retatrutide isn’t a combination of two separate compounds.
It is a single triple receptor agonist designed to activate:
GIP + GLP-1 + glucagon receptors
This three-receptor mechanism is one of the reasons retatrutide has attracted substantial scientific interest.
Retatrutide has also progressed into a large Phase 3 clinical-development programme.
The Fundamental Difference
The easiest way to understand the distinction is:
CagriSema: two compounds targeting GLP-1 and amylin-related pathways.
Retatrutide: one molecule targeting GIP, GLP-1 and glucagon receptors.
So although both investigate multi-pathway metabolic biology, they aren’t using the same biological strategy.
This makes the comparison scientifically interesting.
CagriSema: Combining Complementary Pathways
CagriSema represents a combination approach.
Semaglutide provides GLP-1 receptor agonism, while cagrilintide introduces signalling associated with amylin.
Amylin and GLP-1 are distinct hormones with different receptor systems, although both participate in metabolic regulation.
Researchers are therefore studying whether simultaneously targeting these pathways produces effects that differ from targeting GLP-1 alone.
This reflects a broader trend in metabolic research: investigating complementary biological mechanisms rather than relying on one signalling pathway.
Retatrutide: Triple Receptor Agonism
Retatrutide approaches the same broader scientific challenge differently.
Instead of combining separate compounds, researchers engineered one molecule with activity at three receptors.
These are:
GIP receptor
GLP-1 receptor
Glucagon receptor
Each pathway has a different physiological role.
The scientific question is therefore whether coordinated activity across all three receptors produces a distinct metabolic response.
This concept is generally described as triple agonism.
Is Retatrutide a “GLP-3”?
No.
This has become a common source of confusion online.
Retatrutide is sometimes informally called a “GLP-3,” apparently because it targets three receptors.
However, GLP-3 isn’t the scientific name for retatrutide and there isn’t a GLP-3 receptor involved in its mechanism.
Retatrutide targets GIP, GLP-1 and glucagon receptors.
“Triple agonist” is therefore the more accurate description.
How Do Their Clinical Programmes Differ?
Both programmes have reached advanced clinical development, but their trials shouldn’t be treated as direct head-to-head comparisons.
CagriSema has been studied through Novo Nordisk’s REDEFINE programme.
Retatrutide is being investigated through Eli Lilly’s TRIUMPH programme, alongside additional studies examining type 2 diabetes and other metabolic conditions.
Different trials can involve different:
- participant populations
- study durations
- endpoints
- dosing strategies
- statistical methods
- inclusion criteria
For that reason, percentages reported from separate clinical trials shouldn’t simply be placed next to each other and interpreted as proving that one compound is “better.”
A properly controlled head-to-head study provides much stronger comparative evidence.
Why Are Researchers Moving Beyond GLP-1 Alone?
GLP-1 research transformed the metabolic field, but human metabolism involves numerous interacting signalling systems.
Researchers are therefore increasingly examining additional pathways.
These include:
- GIP
- glucagon
- amylin
- combinations involving GLP-1
- other emerging metabolic targets
CagriSema and retatrutide are two prominent examples of this development.
But they’re far from the only ones.
Where Does Amylin Fit?
Amylin has become particularly important to the next generation of metabolic research.
It is a peptide hormone naturally released from pancreatic beta cells alongside insulin.
Cagrilintide is designed as a long-acting amylin analogue.
Other investigational programmes are also exploring amylin signalling, making the pathway an increasingly important research category alongside GLP-1.
This is why compounds such as cagrilintide and newer GLP-1/amylin approaches are receiving increasing attention.
Which Research Approach Is More Promising?
At this stage, the scientific evidence doesn’t justify reducing these programmes to a simple winner-versus-loser comparison.
They target different biological systems and are being investigated through different clinical programmes.
Their eventual roles will depend on considerably more than a headline percentage from an individual trial.
Researchers and regulators consider factors including efficacy, safety, tolerability, treatment discontinuation, durability of response and outcomes across different populations.
The scientifically useful question is therefore not simply “Which one is better?”
It’s:
What can these different approaches teach researchers about multi-pathway metabolic regulation?
A New Generation of Metabolic Research
CagriSema and retatrutide demonstrate how quickly this research field is changing.
The progression has moved from predominantly single-receptor approaches toward increasingly sophisticated strategies involving several biological pathways.
CagriSema investigates GLP-1 + amylin through a combination approach.
Retatrutide investigates GIP + GLP-1 + glucagon through a single triple-agonist molecule.
Other investigational compounds are exploring still different combinations.
The result is a rapidly expanding research landscape in which GLP-1 is increasingly only one part of a much larger scientific story.
Research Notice: This article is provided for educational and scientific-information purposes. CagriSema and retatrutide remain investigational programmes and this content does not constitute medical advice, treatment guidance or dosing information.